Our mission at LungLife is driven from important and compelling statistical data about lung cancer. We have some exciting news to share. Our company is using artificial intelligence to aid with the early detection of lung cancer. LungLife has developed technology that pairs a simple blood draw with artificial intelligence to provide clinicians and patients the information they need to make informed decisions about the management of lung nodules and lung cancer.
We believe our test can meet the need for a quick and effective aid for evaluation of indeterminant nodules.
Our pilot-study data across 151 participants showed high performance in distinguishing cancerous from non-cancerous indeterminant nodules across all patients regardless of age or smoking history. We believe it will be effective for a broad group of patients. Our LungLB Test also showed high performance in smaller nodules, where existing tools such as position emission tomography (PET) have problems. It was crucially effective in detecting lung cancer early showing 79% sensitivity in Stage I masses.
We are currently carrying out our extended clinical validation study with enrollment expected to be completed early next year. Our hope is the results of the larger study will mirror the results from our pilot study.
Currently about 80% of lung cancer is detected in late stages. Our vision is that our simple test will invert that ratio such that in years to come at least 80% of lung cancer is detected early. Early detection means better care, better outcomes, and longer lives.
We at LungLife strive to be a driving force in the early detection of lung cancer.
For more information about the great work we are doing, visit our website at lunglife.ai.com.